Shakeel Tabish
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $216, 2.3 times the $93 reported in 2019.
Across 20 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$130
- Novartis$101
- MDD US Operations, LLC$53
- Acadia Pharmaceuticals Inc$46
- Biohaven Pharmaceutical Holding Company Ltd.$41
- Teva Pharmaceuticals USA, Inc.$32
- plus $178 from 10 others
What the payments were for
- Speaking & faculty fees$183%
- Food & beverage$56497%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1 | $130 |
| Novartis | 1 | $101 |
| MDD US Operations, LLC | 2 | $53 |
| Acadia Pharmaceuticals Inc | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Argenx US, Inc. | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$130
- KESIMPTA$101
- MAYZENT$101
How this compares
$582 in reported general payments places this provider in the 55th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dimethyl Fumarate | 13 | $37,570 |
| Lacosamide | 42 | $6,116 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 144 | $4,815 |
| Divalproex Sodium | 57 | $3,702 |
| Gabapentin | 201 | $3,649 |
| Levetiracetam | 61 | $3,268 |
| Donepezil Hcl | 175 | $2,873 |
| Carbamazepine | 16 | $1,971 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 48 | $1,933 |
| Pyridostigmine Bromide | 16 | $1,367 |
| Baclofen | 30 | $1,126 |
| Valproic Acid | 14 | $1,069 |
| Riluzole | 14 | $1,031 |
| Atorvastatin Calcium | 81 | $997 |
| Primidone | 37 | $954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $20 | $1,36716 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $35316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 39 neurology providers in North Dakota.
Other neurology in Minot
- Abdullahi Musa AdamuMinot$973
- Rosina MedelMinot$145
- Bahram NicoMinot$91
- Tanya HarlowFargo$73K
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
- Scott BellistonFargo$9K
- James MilesGrand Forks$3K
- Jess MillerBismarck$2K
- Gary MillerFargo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.